Patients with metastatic renal cell carcinoma (mRCC) who have disease progression on the standard dose of sunitinib (Sutent, Pfizer) may experience response with a dose escalation, new results suggested.
Lead investigator Jacques Raphael, MD, of Sunnybrook Odette Cancer Centre, University of Toronto, in Ontario, and his colleagues reviewed medical records of 25 mRCC patients treated with a 50-mg dose of sunitinib between October 2009 and January 2016. All the patients had experienced